The firms other ETFs include the recently launched BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC) and the BioShares Biotechnology Products Fund (NasdaqGM: BBP), which debuted last month.
BBC’s index excludes large pharmaceuticals companies as well as medical devices and diagnostics; life science tools; specialty pharmaceuticals, generic drugs and outsourced drug delivery; healthcare services; contract research organizations; neutraceuticals; agricultural biotechnology; animal health; diversified healthcare; food sciences; information technology; and nanotechnology firms.
BBP tracks the BioShares Biotechnology Products Index, which is also sponsored by LifeSci Index Partners. That index follows U.S.-listed biotech companies with a primary product offering or product candidate that has landed FDA approval, according to the SEC filing. At the end of the second quarter, the index was home to 43 companies. [Nifty New Biotech ETFs]
ETF Trends editorial team contributed to this post.